The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Kasikhina E.I.

State Educational Institution of additional professional education "Russian Academy of Continuous Medical Education"

Savchenko N.V.

Meditsinskiĭ tsentr "Mediko-S", Moskva

Terbinafine generics in Russia: A practical mycologist's opinion

Authors:

Kasikhina E.I., Savchenko N.V.

More about the authors

Read: 4667 times


To cite this article:

Kasikhina EI, Savchenko NV. Terbinafine generics in Russia: A practical mycologist's opinion. Russian Journal of Clinical Dermatology and Venereology. 2012;10(5):80‑84. (In Russ.)

References:

  1. Gerasimov V.B., Luk'yanov S.V. Eshche raz k voprosu o dzhenerikakh. Farm vestn 2004; 18: 336-339.
  2. Carrilo Norte J.A., Postigo Mota S. Generic drugs: we must cut pharmaceutical spending but undertaking drug quality. Rev Enferm 2012; 35: 2: 10-19.
  3. Payette M., Grant-Kels J.M. Generic drugs in dermatology: part I. J Am Acad Dermatol 2012; 66: 3: 343: e1-e8.
  4. FDA. Electronic Orange Book. Approved Drug Products with Therapeutic Equivalence Evaluations 20 ed. 2000.
  5. Payette M., Grant-Kels J.M. Generic drugs in dermatology: part II. J Am Acad Dermatol 2012; 66:3: 353: e1-e15.
  6. Koytchev R., Erenmemisoglu A., van der Meer M.J., Alpan S. Clinical relevance of bioequivalence acceptance criteria. The example of terbinafine. Arzneimittelforschung 2003; 53: 4: 289-293.
  7. Almeida S., Filipe A., Vallée F. et al. Comparative bioavailability of two formulations of terbinafine. Data from a cross- over, randomized, open-label bioequivalence study in healthy volunteers. Arzneimittelforschung 2004; 54: 11: 757-762.
  8. Jiang X., Wang N., Zhang Z. et al. Pharmacokinetics and comparative bioavailability of two terbinafine hydrochloride formulations after single-dose administration in Chinese healthy subjects. Arzneimittelforschung 2008; 58: 7: 363-366.
  9. Batkaev E.A., Verkhoglyad I.V. Sravnitel'naya farmakoekonomicheskaya otsenka primeneniya antimikotikov gruppy terbinafina. Lech vrach 2008; 5: 30-32.
  10. Otchet o rezul'tatakh issledovaniya bioekvivalentnosti preparatov Ekzifin (D-r Reddis Laboratoris Ltd, Indiya) i Lamizil (Novartis, Shveitsariya). Ural'skii nauchno-issledovatel'skii institut dermatovenerologii i immunopatologii MZ RF. Ekaterinburg 2003.
  11. Skripkin Yu.K., Kulagin V.I., Leshchenko V.M. i dr. Vosproizvedennye protivogribkovye preparaty v terapii onikhomikozov: problemy sootvetstviya original'nym antimikotikam i vozmozhnosti klinicheskogo primeneniya. Zhurn dermatovenerol kosmetol 2003; 1: 22-28.
  12. Hoharitanon S., Chaichalotornkul J., Sindhupak W.A. Somparison of efficacy between two itraconazole generic products and the innovative itraconazole in the treatment of tinea pedis. J Med Ass Thai 2005; 88: 4: 167-172.
  13. Alberti I., Kalia Y.N., Naik A. et al. In vivo assessment of enhanced topical delivery of terbinafine to human stratum corneum. J Control Rel 2001; 71: 3: 319-327.
  14. Fedenko E.S., Elisyutina O.G. Rol' gribkovoi infektsii v razvitii atopicheskogo dermatita i tselesoobraznost' protivogribkovoi terapii. Ros allergologich zhurn 2006; 5: 4-13.
  15. Davidova M.E., Ol'khovskaya K.B., Perlamutrov Yu.N. Effektivnost' ekzifina v kompleksnoi terapii bol'nykh atopicheskim dermatitom. Vestn dermatol venerol 2007; 5: 60-62.
  16. Malishevskaya N.P., Nesterov S.N. Sovremennye osobennosti epidemiologii, kliniki i lecheniya mikrosporii. Lech vrach 2004; 1: 56-58.
  17. Antonov V.B. Terbinafin v lechenii onikhomikoza u patsientov s somaticheskimi zabolevaniyami. Lech vrach 2004; 9: 76-78.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.